Taiwan
· Delayed Price · Currency is TWD Syngen Biotech Co.,Ltd. Statistics
Total Valuation
Syngen Biotech Co.,Ltd. has a market cap or net worth of TWD 3.79 billion. The enterprise value is 4.01 billion.
| Market Cap | 3.79B |
| Enterprise Value | 4.01B |
Important Dates
The next estimated earnings date is Wednesday, November 13, 2024.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | Jun 27, 2024 |
Share Statistics
Syngen Biotech Co.,Ltd. has 27.10 million shares outstanding. The number of shares has decreased by -0.00% in one year.
| Shares Outstanding | 27.10M |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | 6.99% |
| Owned by Institutions (%) | 4.23% |
| Float | 10.85M |
Valuation Ratios
The trailing PE ratio is 16.04.
| PE Ratio | 16.04 |
| Forward PE | n/a |
| PS Ratio | 1.98 |
| PB Ratio | 1.80 |
| P/FCF Ratio | 13.54 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.04, with an EV/FCF ratio of 14.30.
| EV / Earnings | 16.94 |
| EV / Sales | 2.09 |
| EV / EBITDA | 10.04 |
| EV / EBIT | 13.71 |
| EV / FCF | 14.30 |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 22.99.
| Current Ratio | 1.72 |
| Quick Ratio | 1.16 |
| Debt / Equity | 22.99 |
| Debt / EBITDA | 1.25 |
| Debt / FCF | 1.73 |
| Interest Coverage | 29.88 |
Financial Efficiency
Return on equity (ROE) is 11.51% and return on invested capital (ROIC) is 6.88%.
| Return on Equity (ROE) | 11.51% |
| Return on Assets (ROA) | 5.61% |
| Return on Capital (ROIC) | 6.88% |
| Revenue Per Employee | 7.76M |
| Profits Per Employee | 957,972 |
| Employee Count | 247 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 3.43 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -16.67% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -16.67% |
| 50-Day Moving Average | 147.57 |
| 200-Day Moving Average | 153.08 |
| Relative Strength Index (RSI) | 50.05 |
| Average Volume (20 Days) | 14,916 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Syngen Biotech Co.,Ltd. had revenue of TWD 1.92 billion and earned 236.62 million in profits. Earnings per share was 8.73.
| Revenue | 1.92B |
| Gross Profit | 667.71M |
| Operating Income | 280.78M |
| Pretax Income | 291.00M |
| Net Income | 236.62M |
| EBITDA | 372.28M |
| EBIT | 280.78M |
| Earnings Per Share (EPS) | 8.73 |
Balance Sheet
The company has 270.59 million in cash and 485.06 million in debt, giving a net cash position of -214.47 million or -7.91 per share.
| Cash & Cash Equivalents | 270.59M |
| Total Debt | 485.06M |
| Net Cash | -214.47M |
| Net Cash Per Share | -7.91 |
| Equity (Book Value) | 2.11B |
| Book Value Per Share | 77.84 |
| Working Capital | 493.20M |
Cash Flow
In the last 12 months, operating cash flow was 372.27 million and capital expenditures -91.96 million, giving a free cash flow of 280.31 million.
| Operating Cash Flow | 372.27M |
| Capital Expenditures | -91.96M |
| Free Cash Flow | 280.31M |
| FCF Per Share | 10.34 |
Margins
Gross margin is 34.85%, with operating and profit margins of 14.65% and 12.35%.
| Gross Margin | 34.85% |
| Operating Margin | 14.65% |
| Pretax Margin | 15.19% |
| Profit Margin | 12.35% |
| EBITDA Margin | 19.43% |
| EBIT Margin | 14.65% |
| FCF Margin | 14.63% |
Dividends & Yields
This stock pays an annual dividend of 5.00, which amounts to a dividend yield of 3.60%.
| Dividend Per Share | 5.00 |
| Dividend Yield | 3.60% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 8 |
| Payout Ratio | 57.27% |
| Buyback Yield | 0.00% |
| Shareholder Yield | 3.60% |
| Earnings Yield | 6.24% |
| FCF Yield | 7.39% |
Stock Splits
The last stock split was on July 9, 2018. It was a forward split with a ratio of 1.1.
| Last Split Date | Jul 9, 2018 |
| Split Type | Forward |
| Split Ratio | 1.1 |